ADC Contract Manufacturing Market

ADC Contract Manufacturing Market (6th Edition): Industry Trends and Global Forecasts, till 2035 – Distribution by Stage of Development (Phase I, Phase II, Phase III and Commercial), Process Component (Antibody, HPAPI / Cytotoxic Payload, Conjugation / Linker and Fill / Finish), Target Indication (Solid Tumors, Hematological Tumors and Others), Antibody Generation (Second, Third, Fourth and Next), Antibody Origin (Humanized, Chimeric, Murine and Others), Antibody Isotype (IgG1, IgG4 and Others), Type of Payload (Auristatin, Camptothecin, DNA Topoisomerase I Inhibitor, Maytansinoid and Others), Type of Linker (Maleimide, SMCC, Tetrapeptide-based linker, Valine-citrulline and Others), and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World)

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    416

  • Pages
    510

  • View Count
    32955

Table Of Contents

1. PREFACE
1.1. ADC Contract Manufacturers: Market Overview
1.2. Market Share Insights
1.3. Market Segmentation Overview
1.4. Key Market Insights
1.5. Report Coverage
1.6. Key Questions Answered
1.7. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates

3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry

3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk

3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION
5.1. Chapter Overview
5.2. Key Components of ADCs
5.2.1. Antibody
5.2.2. Cytotoxin (Payloads)
5.2.3. Linker

5.3. ADC Manufacturing
5.3.1. Key Steps
5.3.2. Technical Challenges
5.3.3. Need for Outsourcing

5.4. Challenges Associated with Supply Chain and Method Transfer
5.4.1. Growing Demand for One-Stop Shops and Integrated Service Providers

5.5. Selecting a CMO Partner
5.6. Future Perspective

6. ADC CONTRACT MANUFACTURERS: MARKET LANDSCAPE
6.1. Chapter Overview
6.2. ADC Contract Manufacturers: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Type of ADC Manufacturing Service Offered
6.2.5. Analysis by Type of Additional Service Offered
6.2.6. Analysis by Scale of Operation
6.2.7. Analysis by Location of Manufacturing Facilities

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. MabPlex
7.2.1. Company Overview
7.2.2. ADC Related Services
7.2.3. Manufacturing Facilities
7.2.4. Recent Developments and Future Outlook

7.3. Lonza
7.3.1. Company Overview
7.3.2. Financial Information
7.3.3. ADC Related Services
7.3.4. Manufacturing Facilities
7.3.5. Recent Developments and Future Outlook

7.4. Abzena
7.4.1. Company Overview
7.4.2. ADC Related Services
7.4.3. Manufacturing Facilities
7.4.4. Recent Developments and Future Outlook

7.5. GBI
7.5.1. Company Overview
7.5.2. ADC Related Services
7.5.3. Manufacturing Facilities
7.5.4. Recent Developments and Future Outlook

7.6. CARBOGEN AMCIS
7.6.1. Company Overview
7.6.2. ADC Related Services
7.6.3. Manufacturing Facilities
7.6.4. Recent Developments and Future Outlook

7.7. Millipore Sigma
7.7.1. Company Overview
7.7.2. ADC Related Offerings
7.7.3. Manufacturing Facilities
7.7.4. Recent Developments and Future Outlook

7.8. WuXi Biologics
7.8.1. Company Overview
7.8.2. Financial Information
7.8.3. ADC Related Services
7.8.4. Manufacturing Facilities
7.8.5. Recent Developments and Future Outlook

7.9. Catalent Pharma Solutions
7.9.1. Company Overview
7.9.2. Financial Information
7.9.3. ADC Related Services
7.9.4. Manufacturing Facilities
7.9.5. Recent Developments and Future Outlook

7.10. Cerbios-Pharma
7.10.1. Company Overview
7.10.2. ADC Related Services
7.10.3. Manufacturing Facilities
7.10.4. Recent Developments and Future Outlook

7.11. Formosa Laboratories
7.11.1. Company Overview
7.11.2. ADC Related Services
7.11.3. Manufacturing Facilities
7.11.4. Recent Developments and Future Outlook

7.12. Sterling Pharma Solutions
7.12.1. Company Overview
7.12.2. ADC Related Services
7.12.3. Manufacturing Facilities
7.12.4. Recent Developments and Future Outlook

7.13. Piramal Pharma Solutions
7.13.1. Company Overview
7.13.2. ADC Related Services
7.13.3. Manufacturing Facilities
7.13.4. Recent Developments and Future Outlook

7.14. AbbVie Contract Manufacturing
7.14.1. Company Overview
7.14.2. ADC Related Services
7.14.3. Manufacturing Facilities
7.14.4. Recent Developments and Future Outlook

8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. ADC Contract Manufacturers: Company Competitiveness Analysis
8.4.1. ADC Contract Manufacturers based in North America (Peer Group I)
8.4.2. ADC Contract Manufacturers based in Europe (Peer Group II)
8.4.3. ADC Contract Manufacturers based in Asia-Pacific (Peer Group III)

8.5. Capability Benchmarking of Top ADC Contract Manufacturers

9. ADC CONTRACT MANUFACTURERS: RECENT EXPANSIONS
9.1. Chapter Overview
9.2. ADC Contract Manufacturers: Recent Expansions
9.2.1. Analysis by Year of Expansion
9.2.2. Analysis by Type of Expansion
9.2.3. Analysis by Purpose of Expansion
9.2.4. Analysis by Scale of Operation
9.2.5. Analysis by Location of Expanded Facility
9.2.6. Most Active Players: Analysis by Number of Expansions

10. ADC CONTRACT MANUFACTURERS: PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. ADC Contract Manufacturers: Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Purpose of Partnership
10.3.4. Analysis by Scale of Operation
10.3.5. Most Active Players: Analysis by Number of Partnerships

10.3.6. Analysis by Geography
10.3.6.1. Intercontinental and Intracontinental Agreements
10.3.6.2. Local and International Agreements

11. MAKE VERSUS BUY DECISION MAKING
11.1. Chapter Overview
11.2. Assumptions and Key Parameters
11.2.1. Scenario 1
11.2.2. Scenario 2
11.2.3. Scenario 3
11.2.4. Scenario 4

11.3. Concluding Remarks

12. VALUE CHAIN ANALYSIS
12.1. Chapter Overview
12.2. ADC Development Value Chain
12.3. Cost Distribution across the Value Chain
12.3.1. Cost Associated with Antibody Manufacturing
12.3.2. Cost Associated with Payload and Linker Manufacturing
12.3.3. Cost Associated with Conjugation
12.3.4. Cost Associated with Fill / Finish

13. ADC MANUFACTURING: CAPACITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. ADC Manufacturing: Global Installed Capacity
13.3.1. Analysis by Company Size
13.3.2. Analysis by Location of Headquarters

13.3.3. Analysis by Location of Manufacturing Facilities
13.3.3.1 Analysis by Region
13.3.3.2. Analysis by Country

13.3.4. Analysis by Key Players

14. ADC THERAPEUTICS: MARKET OVERVIEW
14.1. Chapter Overview
14.2. Antibody Drug Conjugates: Therapies Pipeline
14.2.1. Analysis by Status of Development
14.2.2. Analysis by Target Disease Indication
14.2.3. Analysis by Therapeutic Area
14.2.4. Analysis by Line of Treatment
14.2.5. Analysis by Dosing Frequency
14.2.6. Analysis by Type of Therapy
14.2.7. Analysis by Target Antigen
14.2.8. Analysis by Antibody Isotype
14.2.9. Analysis by Payload / Cytotoxin / Warhead
14.2.10. Analysis by Type of Payload
14.2.11. Analysis by Linker
14.2.12. Analysis by Type of Linker (Cleavable / Non-Cleavable)

14.3. Antibody Drug Conjugates: Therapies to Watch
14.4. Concluding Remarks

15. CLINICAL TRIAL ANALYSIS
15.1. Chapter Overview
15.2. Scope and Methodology
15.3. Antibody Drug Conjugates: Clinical Trial Analysis
15.3.1. Analysis by Trial Registration Year
15.3.2. Analysis by Trial Status
15.3.3. Analysis of Enrolled Patient Population by Trial Status
15.3.4. Analysis by Trial Registration Year and Trial Status
15.3.5. Analysis of Enrolled Patient Population by Trial Registration Year
15.3.6. Analysis by Trial Phase
15.3.7. Analysis of Enrolled Patient Population by Trial Phase
15.3.8. Analysis by Type of Sponsor / Collaborator
15.3.9. Analysis by Target Population
15.3.10. Analysis by Study Design
15.3.11. Most Active Industry Players: Analysis by Number of Trials
15.3.12. Most Active Non-Industry Players: Analysis by Number of Trials
15.3.13. Analysis of Clinical Trials by Geography
15.3.14. Analysis of Enrolled Patient Population by Geography

16. LIKELY PARTNER ANALYSIS
16.1. Chapter Overview
16.2. Scoring Criteria and Key Assumptions
16.3. Scope and Methodology
 
16.4. Potential Strategic Partners based in North America
16.4.1. Most Likely Partners
16.4.2. Likely Partners
16.4.3. Least Likely Partners

16.5. Potential Strategic Partners based in Europe
16.5.1. Most Likely Partners
16.5.2. Likely Partners
16.5.3. Least Likely Partners

16.6. Potential Strategic Partners based in Asia-Pacific and Rest of the World
16.6.1. Most Likely Partners
16.6.2. Likely Partners
16.6.3. Least Likely Partners

17. ADC THERAPEUTICS: DEMAND ANALYSIS
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. ADC Therapeutics: Global Annual Demand
17.3.1. ADC Therapeutics: Annual Commercial Demand
17.3.1.1. Analysis by Target Indication
17.3.1.2. Analysis by Antibody Origin
17.3.1.3. Analysis by Antibody Isotype
17.3.1.4. Analysis by Type of Payload
17.3.1.5. Analysis by Type of Linker
17.3.1.6 Analysis by Key Geographical Regions

17.3.2. ADC Therapeutics: Annual Clinical Demand
17.3.2.1. Analysis by Phase of Development
17.3.2.2. Analysis by Target Indication
17.3.2.3. Analysis by Antibody Origin
17.3.2.4. Analysis by Antibody Isotype
17.3.2.5. Analysis by Type of Payload
17.3.2.6. Analysis by Type of Linker
17.3.2.7. Analysis by Key Geographical Regions

18. REGIONAL CAPABILITY ANALYSIS
18.1. Chapter Overview
18.2. Assumptions and Key Parameters
18.3. ADC Contract Manufacturing Capabilities in North America
18.4. ADC Contract Manufacturing Capabilities in Europe
18.5. ADC Contract Manufacturing Capabilities in Asia-Pacific and Rest of the World

19. ATTRACTIVENESS COMPETETIVENESS MATRIX
19.1. Chapter Overview
19.2. AC Matrix: Overview
19.2.1. Strong Business Segments
19.2.2. Average Business Segments
19.2.3. Weak Business Segments

19.3. AC Matrix: Analytical Methodology

19.4. AC Matrix: Overall ADC Contract Manufacturing Market Scenario
19.4.1. AC Matrix: ADC Contract Manufacturing Scenario for Type of ADC Manufacturing Service Offered
19.4.2. AC Matrix: ADC Contract Manufacturing Scenario for Key Geographical Regions

20. ADC CONTRACT MANUFACTURING MARKET
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Global ADC Therapeutics Market, Historical Trends and Forecasted Estimates, till 2035
20.4. Global ADC Contract Manufacturing Market, Historical Trends and Forecasted Estimates, till 2035
20.4.1. Scenario Analysis

20.5. Key Market Segmentations

21. ADC CONTRACT MANUFACTURING MARKET, BY STAGE OF DEVELOPMENT
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. ADC Contract Manufacturing Market: Distribution by Stage of Development, 2023, 2028 and 2035
21.3.1. Phase I: Forecasted Estimates, till 2035
21.3.2. Phase II: Forecasted Estimates, till 2035
21.3.3. Phase III: Forecasted Estimates, till 2035
21.3.4. Commercial: Forecasted Estimates, till 2035

21.4. Data Triangulation and Validation

22. ADC CONTRACT MANUFACTURING MARKET, BY PROCESS COMPONENT
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. ADC Contract Manufacturing Market: Distribution by Process Component, 2023, 2028 and 2035
22.3.1. Antibody: Forecasted Estimates, till 2035
22.3.2. HPAPI / Cytotoxic Payload: Forecasted Estimates, till 2035
22.3.3. Conjugation / Linker: Forecasted Estimates, till 2035
22.3.4. Fill / Finish: Forecasted Estimates, till 2035

22.4. Data Triangulation and Validation

23. ADC CONTRACT MANUFACTURING MARKET, BY TARGET INDICATION
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. ADC Contract Manufacturing Market: Distribution by Target Indication, 2023, 2028 and 2035
23.3.1. Solid Tumors: Forecasted Estimates, till 2035
23.3.2. Hematological Tumors: Forecasted Estimates, till 2035
23.3.3. Others: Forecasted Estimates, till 2035

23.4. Data Triangulation and Validation

24. ADC CONTRACT MANUFACTURING MARKET, BY ANTIBODY GENERATION
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. ADC Contract Manufacturing Market: Distribution by Antibody Generation, 2023, 2028 and 2035
24.3.1. Second Generation: Forecasted Estimates, till 2035
24.3.2. Third Generation: Forecasted Estimates, till 2035
24.3.3. Fourth Generation: Forecasted Estimates, till 2035
24.3.4. Next Generation: Forecasted Estimates, till 2035

24.4. Data Triangulation and Validation

25. ADC CONTRACT MANUFACTURING MARKET, BY ANTIBODY ORIGIN
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. ADC Contract Manufacturing Market: Distribution by Antibody Origin, 2023, 2028 and 2035
25.3.1. Human Origin: Forecasted Estimates, till 2035
25.3.2. Chimeric Origin: Forecasted Estimates, till 2035
25.3.3. Murine Origin: Forecasted Estimates, till 2035
25.3.4. Others: Forecasted Estimates, till 2035

25.4. Data Triangulation and Validation

26. ADC CONTRACT MANUFACTURING MARKET, BY ANTIBODY ISOTYPE
26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. ADC Contract Manufacturing Market: Distribution by Antibody Isotype, 2023, 2029 and 2035
26.3.1. IgG1: Forecasted Estimates, till 2035
26.3.2. IgG4: Forecasted Estimates, till 2035
26.3.3. Others: Forecasted Estimates, till 2035

26.4. Data Triangulation and Validation

27. ADC CONTRACT MANUFACTURING MARKET, BY TYPE OF PAYLOAD
27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. ADC Contract Manufacturing Market: Distribution by Type of Payload, 2023, 2029 and 2035
27.3.1.Camptothecin: Forecasted Estimates, till 2035
27.3.2. Maytansinoid: Forecasted Estimates, till 2035
27.3.3. Auristatin: Forecasted Estimates, till 2035
27.3.4. DNA topoisomerase I inhibitor: Forecasted Estimates, till 2035
27.3.5. Others: Forecasted Estimates, till 2035

27.4. Data Triangulation and Validation

28. ADC CONTRACT MANUFACTURING MARKET, BY TYPE OF LINKER
28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. ADC Contract Manufacturing Market: Distribution by Type of Linker, 2023, 2029 and 2035
28.3.1. Maleimide: Forecasted Estimates, till 2035
28.3.2. SMCC: Forecasted Estimates, till 2035
28.3.3. Tetrapeptide-based linker: Forecasted Estimates, till 2035
28.3.4. Valine-citrulline: Forecasted Estimates, till 2035
28.3.5. Others: Forecasted Estimates, till 2035

28.4. Data Triangulation and Validation

29. ADC CONTRACT MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS
29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, 2023, 2029 and 2035
29.3.1. North America: Forecasted Estimates, till 2035
29.3.2. Europe: Forecasted Estimates, till 2035
29.3.3. Asia-Pacific and Rest of the World: Forecasted Estimates, till 2035

29.4. Data Triangulation and Validation

30. COMMERCIAL ADC CONTRACT MANUFACTURING MARKET
30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Commercial ADC Contract Manufacturing Market, Forecasted Estimates, till 2035
30.3.1. Commercial ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035
30.3.2. Commercial ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035
30.3.3. Commercial ADC Contract Manufacturing Market: Distribution by Antibody Generation, Forecasted Estimates, till 2035
30.3.4. Commercial ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035
30.3.5. Commercial ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035
30.3.6. Commercial ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035
30.3.7. Commercial ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035
30.3.8. Commercial ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035

30.4. Data Triangulation and Validation

31. CLINICAL ADC CONTRACT MANUFACTURING MARKET
31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3. Clinical ADC Contract Manufacturing Market, Forecasted Estimates, till 2035
31.3.1. Clinical ADC Contract Manufacturing Market: Distribution by Phase of Development, Forecasted Estimates, till 2035
31.3.2. Clinical ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035
31.3.3. Clinical ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035
31.3.4. Clinical ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035
31.3.5. Clinical ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035
31.3.6. Clinical ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035
31.3.7. Clinical ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035
31.3.8. Clinical ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035

31.4. Data Triangulation and Validation

32. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
32.1. Chapter Overview
32.2. Market Drivers
32.3. Market Restraints
32.4. Market Opportunities
32.5. Market Challenges
32.6. Conclusion

33. CONCLUDING REMARKS

34. INTERVIEW TRANSCRIPTS
34.1. Chapter Overview
34.2. Company A
34.2.1. Company Snapshot
34.2.2. Interview Transcript: Chief Executive Officer and Technical Business Development Manager

34.3. Company B
34.3.1. Company Snapshot
34.3.2. Interview Transcript: Chief Executive Officer and Founder

34.4. Company C
34.4.1. Company Snapshot
34.4.2. Interview Transcript: Former Chief Executive Officer

34.5. Company D
34.5.1. Company Snapshot
34.5.2. Interview Transcript: Chief Executive Officer and Co-Founder

34.6. Company E
34.6.1. Company Snapshot
34.6.2. Interview Transcript: Chief Commercial Officer

34.7. Company F
34.7.1. Company Snapshot
34.7.2. Interview Transcript: Chief Business Officer

34.8. Company G
34.8.1. Company Snapshot
34.8.2. Interview Transcript: Executive Director and Chief Innovation Officer

34.9. Company H
34.9.1. Company Snapshot
34.9.2. Interview Transcript: Director, Business Development

34.10. Company I
34.10.1. Company Snapshot
34.10.2. Interview Transcript: Former Director of CDMO

34.11. Company J
34.11.1. Company Snapshot
34.11.2. Interview Transcript: Director Corporate Development

34.12. Company K
34.12.1. Company Snapshot
34.12.2. Interview Transcript: Business Development Manager

34.13. Company L
34.13.1. Company Snapshot
34.13.2. Interview Transcript: Director, Business Development and Former Group Product Manager

34.14. Company M
34.14.1. Company Snapshot
34.14.2. Interview Transcript: Former Head of Bioconjugates Commercial Development

34.15. Company N
34.15.1. Company Snapshot
34.15.2. Interview Transcript: Former Site Head

34.16. Company O
34.16.1. Company Snapshot
34.16.2. Interview Transcript: Associate General Manager

34.17. Interview Transcript: Director, Business Development, Leading CMO
34.18. Interview Transcript: Chief Executive Officer, Leading CMO

35. APPENDIX I: TABULATED DATA

36. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentation
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Market Landscape
Figure 4.2 Executive Summary: Recent Expansions
Figure 4.3 Executive Summary: Partnerships and Collaborations
Figure 4.4 Executive Summary: Capacity Analysis
Figure 4.5 Executive Summary: Clinical Trial Analysis
Figure 4.6 Executive Summary: Demand Analysis
Figure 4.7 Executive Summary: Market Sizing and Opportunity Analysis
Figure 5.1 Key Components of an ADC
Figure 5.2 ADC Manufacturing Steps
Figure 5.3 Key Parameters while Selecting a CMO Partner
Figure 6.1 ADC Contract Manufacturers: Distribution by Year of Establishment
Figure 6.2 ADC Contract Manufacturers: Distribution by Company Size
Figure 6.3 ADC Contract Manufacturers: Distribution by Location of Headquarters(Region)
Figure 6.4 ADC Contract Manufacturers: Distribution by Location of Headquarters(Country)
Figure 6.5 ADC Contract Manufacturers: Distribution by Company Size and Location of Headquarters
Figure 6.6 ADC Contract Manufacturers: Distribution by Type of ADC Manufacturing Service Offered
Figure 6.7 ADC Contract Manufacturers: Distribution by Location of Headquartersand ADC Manufacturing Service Offered
Figure 6.8 ADC Contract Manufacturers: Distribution by Type of Additional Service Offered
Figure 6.9 ADC Contract Manufacturers: Distribution by Scale of Operation
Figure 6.10 ADC Contract Manufacturers: Distribution by Type of ADC Manufacturing Service Offered and Scale of Operation
Figure 6.11 ADC Contract Manufacturers: Distribution by Location of Manufacturing Facilities and Type of ADC Manufacturing Service Offered
Figure 7.1 Lonza: Annual Revenues, FY 2019-H1 FY 2023 (CHF Billion)
Figure 7.2 WuXi Biologics: Annual Revenues, FY 2019-H1 FY 2023 (RMB Billion)
Figure 7.3 Catalent Pharma Solutions: Annual Revenues, FY 2019 - FY 2023 (USD Billion)
Figure 8.1 Company Competitiveness Analysis: ADC Contract Manufacturers based in North America
Figure 8.2 Company Competitiveness Analysis: ADC Contract Manufacturers based in Europe
Figure 8.3 Company Competitiveness Analysis: ADC Contract Manufacturers based in Asia-Pacific
Figure 8.4 Capability Benchmarking: Distribution of Top 9 Players (Wind Rose Representation)
Figure 9.1 Recent Expansions: Cumulative Year-wise Trend, 2013-2023
Figure 9.2 Recent Expansions: Distribution by Type of Expansion
Figure 9.3 Recent Expansions: Distribution by Purpose of Expansion
Figure 9.4 Recent Expansions: Distribution by Year of Expansion and Purpose of Expansion
Figure 9.5 Recent Expansions: Distribution by Scale of Operation
Figure 9.6 Recent Expansions: Distribution by Location of Expanded Facility
Figure 9.7 Recent Expansions: Distribution by Location of Expanded Facility and Scale of Operation
Figure 9.8 Most Active Players: Distribution by Number of Expansions
Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2012-2023
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 10.4 Partnerships and Collaborations: Distribution by Purpose of Partnership
Figure 10.5 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 10.6 Most Active Players: Distribution by Number of Partnership Instances
Figure 10.7 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Figure 10.8 Partnerships and Collaborations: Distribution by Local and International Agreements
Figure 11.1 Make versus Buy Decision Making Framework
Figure 11.2 Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 12.1 Value Chain Analysis: ADC Development Overview
Figure 12.2 Value Chain Analysis: ADC Contract Manufacturing Overview
Figure 12.3 ADC Therapeutics: Distribution by Cost of Raw Material Required for Clinical Stage Manufacturing
Figure 12.4 Value Chain Analysis: Distribution by Cost
Figure 12.5 Costs Associated with Antibody Manufacturing
Figure 12.6 Costs Associated with Payload and Linker Manufacturing
Figure 12.7 Costs Associated with Conjugation
Figure 12.8 Costs Associated with Fill / Finish
Figure 13.1 Global Installed ADC Manufacturing Capacity: Distribution by Company Size
Figure 13.2 Global Installed ADC Manufacturing Capacity: Distribution by Location of Headquarters
Figure 13.3 Global Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (Region)
Figure 13.4 Global Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (Country)
Figure 13.5 Global Installed ADC Manufacturing Capacity: Distribution by Key Players
Figure 14.1 Antibody Drug Conjugates: Distribution by Status of Development
Figure 14.2 Antibody Drug Conjugates: Distribution by Target Disease Indication
Figure 14.3 Antibody Drug Conjugates: Distribution by Therapeutic Area
Figure 14.4 Antibody Drug Conjugates: Distribution by Line of Treatment
Figure 14.5 Antibody Drug Conjugates: Distribution by Dosing Frequency
Figure 14.6 Antibody Drug Conjugates: Distribution by Type of Therapy
Figure 14.7 Antibody Drug Conjugates: Distribution by Target Antigen
Figure 14.8 Antibody Drug Conjugates: Distribution by Antibody Isotype
Figure 14.9 Antibody Drug Conjugates: Distribution by Payload / Cytotoxin / Warhead
Figure 14.10 Antibody Drug Conjugates: Distribution by Type of Payload
Figure 14.11 Antibody Drug Conjugates: Distribution by Linker
Figure 14.12 Antibody Drug Conjugates: Distribution by Type of Linker
Figure 15.1 Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2016-2023
Figure 15.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 15.3 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status
Figure 15.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2016-2023
Figure 15.5 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, 2016-2023
Figure 15.6 Clinical Trial Analysis: Distribution by Trial Phase
Figure 15.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 15.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 15.9 Clinical Trial Analysis: Distribution by Target Population
Figure 15.10 Clinical Trial Analysis: Distribution by Study Design
Figure 15.11 Most Active Industry Players: Distribution by Number of Trials
Figure 15.12 Most Active Non-Industry Players: Distribution by Number of Trials
Figure 15.13 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Figure 15.14 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Figure 17.1 Global Demand for ADC Therapeutics, 2023-2035 (in kg)
Figure 17.2 Global Demand for ADC Therapeutics: Distribution by Stage of Development, 2023-2035 (in kg)
Figure 17.3 Global Commercial Demand for ADC Therapeutics, 2023-2035 (in kg)
Figure 17.4 Global Commercial Demand for ADC Therapeutics: Distribution by Target Indication, 2023-2035 (in kg)
Figure 17.5 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Origin, 2023-2035 (in kg)
Figure 17.6 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2023-2035 (in kg)
Figure 17.7 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Payload, 2023-2035 (in kg)
Figure 17.8 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Linker, 2023-2035 (in kg)
Figure 17.9 Global Commercial Demand for ADC Therapeutics: Distribution by Geography, 2023-2035 (in kg)
Figure 17.10 Global Clinical Demand for ADC Therapeutics, 2023-2035 (in kg)
Figure 17.11 Global Clinical Demand for ADC Therapeutics: Distribution by Phase of Development, 2023-2035 (in kg)
Figure 17.12 Global Clinical Demand for ADC Therapeutics: Distribution by Target Indication, 2023-2035 (in kg)
Figure 17.13 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Origin, 2022-2035 (in kg)
Figure 17.14 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2023-2035 (in kg)
Figure 17.15 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Payload, 2023-2035 (in kg)
Figure 17.16 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Linker, 2023-2035 (in kg)
Figure 17.17 Global Clinical Demand for ADC Therapeutics: Distribution by Geography, 2023-2035 (in kg)
Figure 18.1 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in North America
Figure 18.2 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in Europe
Figure 18.3 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in Asia-Pacific and Rest of the World
Figure 19.1 AC Matrix: Pictorial Representation
Figure 19.2 AC Matrix: Overall ADC Contract Manufacturing Market Scenario, 2023-2028 and 2029-2035
Figure 19.3 AC Matrix: ADC Contract Manufacturing Scenario for Type of ADC Manufacturing Service Offered
Figure 19.4 AC Matrix: ADC Contract Manufacturing Scenario for Key Geographical Regions
Figure 20.1 Global ADC Contract Manufacturing Market, Historical Trends and Forecasted Estimates, till 2035
Figure 20.2 Global ADC Contract Manufacturing Market, Forecasted Estimates, till 2035, Base Scenario (USD Million)
Figure 20.3 Global ADC Contract Manufacturing Market, Forecasted Estimates, till 2035, Conservative Scenario (USD Million)
Figure 20.4 Global ADC Contract Manufacturing Market, Forecasted Estimates, till 2035, Optimistic Scenario (USD Million)
Figure 21.1 Global ADC Contract Manufacturing Market: Distribution by Stage of Development, 2023, 2028 and 2035 (USD Million)
Figure 21.2 ADC Contract Manufacturing Market for Phase I ADCs, Forecasted Estimates, till 2035 (USD Million)
Figure 21.3 ADC Contract Manufacturing Market for Phase II ADCs, Forecasted Estimates, till 2035 (USD Million)
Figure 21.4 ADC Contract Manufacturing Market for Phase III ADCs, Forecasted Estimates, till 2035 (USD Million)
Figure 21.5 ADC Contract Manufacturing Market for Commercial ADCs, Forecasted Estimates, till 2035 (USD Million)
Figure 22.1 Global ADC Contract Manufacturing Market: Distribution by Process Component, 2023, 2028 and 2035 (USD Million)
Figure 22.2 ADC Contract Manufacturing Market for Antibody, Forecasted Estimates, till 2035 (USD Million)
Figure 22.3 ADC Contract Manufacturing Market for HPAPI / Cytotoxic Payload, Forecasted Estimates, till 2035 (USD Million)
Figure 22.4 ADC Contract Manufacturing Market for Conjugation / Linker, Forecasted Estimates, till 2035 (USD Million)
Figure 22.5 ADC Contract Manufacturing Market for Fill / Finish, Forecasted Estimates, till 2035 (USD Million)
Figure 23.1 Global ADC Contract Manufacturing Market: Distribution by Target Indication, 2023, 2028 and 2035 (USD Million)
Figure 23.2 ADC Contract Manufacturing Market for Solid Tumors, Forecasted Estimates, till 2035 (USD Million)
Figure 23.3 ADC Contract Manufacturing Market for Hematological Tumors, Forecasted Estimates, till 2035 (USD Million)
Figure 23.4 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Million)
Figure 24.1 Global ADC Contract Manufacturing Market: Distribution by Antibody Generation, 2023, 2028 and 2035 (USD Million)
Figure 24.2 ADC Contract Manufacturing Market for Second Generation, Forecasted Estimates, till 2035 (USD Million)
Figure 24.3 ADC Contract Manufacturing Market for Third Generation, Forecasted Estimates, till 2035 (USD Million)
Figure 24.4 ADC Contract Manufacturing Market for Fourth Generation, Forecasted Estimates, till 2035 (USD Million)
Figure 24.5 ADC Contract Manufacturing Market for Next Generation, Forecasted Estimates, till 2035 (USD Million)
Figure 25.1 Global ADC Contract Manufacturing Market: Distribution by Antibody Origin, 2023, 2028 and 2035 (USD Million)
Figure 25.2 ADC Contract Manufacturing Market for Humanized Origin, Forecasted Estimates, till 2035 (USD Million)
Figure 25.3 ADC Contract Manufacturing Market for Chimeric Origin, Forecasted Estimates, till 2035 (USD Million)
Figure 25.4 ADC Contract Manufacturing Market for Murine Origin, Forecasted Estimates, till 2035 (USD Million)
Figure 25.5 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Million)
Figure 26.1 Global ADC Contract Manufacturing Market: Distribution by Antibody Isotype, 2023, 2028 and 2035 (USD Million)
Figure 26.2 ADC Contract Manufacturing Market for IgG1, Forecasted Estimates, till 2035 (USD Million)
Figure 26.3 ADC Contract Manufacturing Market for IgG4, Forecasted Estimates, till 2035 (USD Million)
Figure 26.4 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Million)
Figure 27.1 Global ADC Contract Manufacturing Market: Distribution by Type of Payload, 2023, 2028 and 2035 (USD Million)
Figure 27.2 ADC Contract Manufacturing Market for Camptothecin, Forecasted Estimates, till 2035 (USD Billion)
Figure 27.3 ADC Contract Manufacturing Market for Maytansinoid, Forecasted Estimates, till 2035 (USD Billion)
Figure 27.4 ADC Contract Manufacturing Market for Auristatin, Forecasted Estimates, till 2035 (USD Billion)
Figure 27.5 ADC Contract Manufacturing Market for DNA Topoisomerase I Inhibitor, Forecasted Estimates, till 2035 (USD Billion)
Figure 27.6 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Million)
Figure 28.1 Global ADC Contract Manufacturing Market: Distribution by Type of Linker, 2023, 2028 and 2035 (USD Million)
Figure 28.2 ADC Contract Manufacturing Market for Maleimide, Forecasted Estimates, till 2035 (USD Million)
Figure 28.3 ADC Contract Manufacturing Market for SMCC, Forecasted Estimates, till 2035 (USD Million)
Figure 28.4 ADC Contract Manufacturing Market for Tetrapeptide-based linker, Forecasted Estimates, till 2035 (USD Million)
Figure 28.5 ADC Contract Manufacturing Market for Valine-citrulline, Forecasted Estimates, till 2035 (USD Million)
Figure 28.6 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Million)
Figure 29.1 Global ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035 (USD Million)
Figure 29.2 ADC Contract Manufacturing Market in North America, Forecasted Estimates, till 2035 (USD Million)
Figure 29.3 ADC Contract Manufacturing Market in Europe, Forecasted Estimates, till 2035 (USD Million)
Figure 29.4 ADC Contract Manufacturing Market in Asia-Pacific and Rest of the World, Forecasted Estimates, till 2035 (USD Million)
Figure 30.1 Commercial ADC Contract Manufacturing Market, Forecasted Estimates, till 2035 (USD Million)
Figure 30.2 Commercial ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035 (USD Million)
Figure 30.3 Commercial ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035 (USD Million)
Figure 30.4 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Generation, Forecasted Estimates, till 2035 (USD Million)
Figure 30.5 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035 (USD Million)
Figure 30.6 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035 (USD Million)
Figure 30.7 Commercial ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035 (USD Million)
Figure 30.8 Commercial ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035 (USD Million)
Figure 30.9 Commercial ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035 (USD Million)
Figure 31.1 Clinical ADC Contract Manufacturing Market, Forecasted Estimates, till 2035 (USD Million)
Figure 31.2 Clinical ADC Contract Manufacturing Market: Distribution by Phase of Development, Forecasted Estimates, till 2035 (USD Million)
Figure 31.3 Clinical ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035 (USD Million)
Figure 31.4 Clinical ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035 (USD Million)
Figure 31.5 Clinical ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035 (USD Million)
Figure 31.6 Clinical ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035 (USD Million)
Figure 31.7 Clinical ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035 (USD Million)
Figure 31.8 Clinical ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035 (USD Million)
Figure 31.9 Clinical ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035 (USD Million)
Figure 33.1 Concluding Remarks: Market Landscape
Figure 33.2 Concluding Remarks: Recent Expansions
Figure 33.3 Concluding Remarks: Partnerships and Collaborations
Figure 33.4 Concluding Remarks: Clinical Trial Analysis
Figure 33.5 Concluding Remarks: Likely Partner Analysis
Figure 33.6 Concluding Remarks: Capacity Analysis
Figure 33.7 Concluding Remarks: Demand Analysis
Figure 33.8 Concluding Remarks: Market Sizing and Opportunity Analysis (1/3)
Figure 33.9 Concluding Remarks: Market Sizing and Opportunity Analysis (2/3)
Figure 33.10 Concluding Remarks: Market Sizing and Opportunity Analysis (3/3)

List Of Tables

Table 5.1 Common Cytotoxins used for the Production od ADCs
Table 5.2 Safebridge Categorization / OEL Bands for Highly Potent / Cytotoxic Compounds
Table 6.1 ADC Contract Manufacturers: Information on Year of Establishment, Company Size, Location of Headquarters and Type of Manufacturer
Table 6.2 ADC Contract Manufacturers: Information on Type of ADC Manufacturing Service Offered
Table 6.3 ADC Contract Manufacturers: Information on Type of Additional Service Offered and Scale of Operation
Table 6.4 ADC Contract Manufacturers: Information on Location of Manufacturing Facilities and Type of ADC Manufacturing Service Offered
Table 7.1 List of Companies Profiled
Table 7.2 MabPlex: Company Overview
Table 7.3 MabPlex: ADC Related Services
Table 7.4 MabPlex: Information on Manufacturing Facilities
Table 7.5 Lonza: Company Overview
Table 7.6 Lonza: ADC Related Services
Table 7.7 Lonza: Information on Manufacturing Facilities
Table 7.8 Lonza: Recent Developments and Future Outlook
Table 7.9 Abzena: Company Overview
Table 7.10 Abzena: ADC Related Services
Table 7.11 Abzena: Information on Manufacturing Facilities
Table 7.12 Abzena: Recent Developments and Future Outlook
Table 7.13 GBI: Company Overview
Table 7.14 GBI: ADC Related Services
Table 7.15 GBI: Information on Manufacturing Facilities
Table 7.16 CARBOGEN AMCIS: Company Overview
Table 7.17 CARBOGEN AMCIS: ADC Related Services
Table 7.18 CARBOGEN AMCIS: Information on Manufacturing Facilities
Table 7.19 CARBOGEN AMCIS: Recent Developments and Future Outlook
Table 7.20 Millipore Sigma: Company Overview
Table 7.21 Millipore Sigma: ADC Related Services
Table 7.22 Millipore Sigma: Information on Manufacturing Facilities
Table 7.23 WuXi Biologics: Company Overview
Table 7.24 WuXi Biologics: ADC Related Services
Table 7.25 WuXi Biologics: Information on Manufacturing Facilities
Table 7.26 WuXi Biologics: Recent Developments and Future Outlook
Table 7.27 Catalent Pharma Solutions: Company Overview
Table 7.28 Catalent Pharma Solutions: ADC Related Services
Table 7.29 Catalent Pharma Solutions: Information on Manufacturing Facilities
Table 7.30 Catalent Pharma Solutions: Recent Developments and Future Outlook
Table 7.31 Cerbios-Pharma: Company Overview
Table 7.32 Cerbios-Pharma: ADC Related Services
Table 7.33 Cerbios-Pharma: Information on Manufacturing Facilities
Table 7.34 Cerbios-Pharma: Recent Developments and Future Outlook
Table 7.35 Formosa Laboratories: Company Overview
Table 7.36 Formosa Laboratories: ADC Related Services
Table 7.37 Formosa Laboratories: Information on Manufacturing Facilities
Table 7.38 Sterling Pharma Solutions: Company Overview
Table 7.39 Sterling Pharma Solutions: ADC Related Services
Table 7.40 Sterling Pharma Solutions: Information on Manufacturing Facilities
Table 7.41 Sterling Pharma Solutions: Recent Developments and Future Outlook
Table 7.42 Piramal Pharma Solutions: Company Overview
Table 7.43 Piramal Pharma Solutions: ADC Related Services
Table 7.44 Piramal Pharma Solutions: Information on Manufacturing Facilities
Table 7.45 Piramal Pharma Solutions: Recent Developments and Future Outlook
Table 7.46 AbbVie Contract Manufacturing: Company Overview
Table 7.47 AbbVie Contract Manufacturing: ADC Related Services
Table 7.48 AbbVie Contract Manufacturing: Information on Manufacturing Facilities
Table 9.1 ADC Contract Manufacturers: Information on Month and Year of Expansion, Type of Expansion, Purpose of Expansion and Scale of Operation, 2019-2023
Table 9.2 ADC Contract Manufacturers: Information on Location of Expanded Facility and Type of Facility
Table 10.1 ADC Contract Manufacturers: Information on Year of Partnership, Type of Partnership, Purpose of Partnership and Scale of Operation, 2019-2023
Table 10.2 ADC Contract Manufacturers: Information on Type of Agreement (Country and Continent)
Table 12.1 ADC Components: Information on Cost of Cytotoxins
Table 12.2 ADC Components: Information on Cost of Linkers
Table 13.1 Global Installed ADC Contract Manufacturing Capacity: Sample Data Set (Yield)
Table 13.2 Global Installed ADC Contract Manufacturing Capacity: Sample Data Set (Average Capacity)
Table 13.3 Global Installed ADC Manufacturing Capacity: Information on Total Capacity based on CompanySize
Table 14.1 Antibody Drug Conjugates: Information on Drug Candidates, Developers, Status of Development,Target Disease Indication and Therapeutic Area
Table 14.2 Antibody Drug Conjugates to Watch: Information on Drug Candidates, Developer, Status of Development, Target Disease Indication and Therapeutic Area
Table 16.1 Most Likely Partners based in North America
Table 16.2 Likely Partners based in North America
Table 16.3 Least Likely Partners based in North America
Table 16.4 Most Likely Partners based in Europe
Table 16.5 Likely Partners based in Europe
Table 16.6 Least Likely Partners based in Europe
Table 16.7 Most Likely Partners based in Asia-Pacific and Rest of the World
Table 16.8 Likely Partners based in Asia-Pacific and Rest of the World
Table 16.9 Least Likely Partners based in Asia-Pacific and Rest of the World
Table 17.1 List of Late Stage ADCs
Table 34.1 BSP Pharmaceuticals: Key Highlights
Table 34.2 Oxford BioTherapeutics: Key Highlights
Table 34.3 Abzena: Key Highlights
Table 34.4 Syndivia: Key Highlights
Table 34.5 Cerbios-Pharma: Key Highlights
Table 34.6 NBE-Therapeutics: Key Highlights
Table 34.7 Eisai: Key Highlights
Table 34.8 Synaffix: Key Highlights
Table 34.9 Pierre Fabre: Key Highlights
Table 34.10 Goodwin Biotechnology: Key Highlights
Table 34.11 Cerbios-Pharma: Key Highlights
Table 34.12 Catalent Pharma Solutions: Key Highlights
Table 34.13 Lonza: Key Highlights
Table 34.14 Piramal Pharma Solutions: Key Highlights
Table 34.15 Ajinomoto Bio-Pharma Services: Key Highlights
Table 35.1 ADC Contract Manufacturers: Distribution by Year of Establishment
Table 35.2 ADC Contract Manufacturers: Distribution by Company Size
Table 35.3 ADC Contract Manufacturers: Distribution by Location of Headquarters (Region)
Table 35.4 ADC Contract Manufacturers: Distribution by Location of Headquarters (Country)
Table 35.5 ADC Contract Manufacturers: Distribution by Company Size and Location of Headquarters
Table 35.6 ADC Contract Manufacturers: Distribution by Type of ADC Manufacturing Service Offered
Table 35.7 ADC Contract Manufacturers: Distribution by Location of Headquarters and ADC Manufacturing Service Offered
Table 35.8 ADC Contract Manufacturers: Distribution by Type of Additional Service Offered
Table 35.9 ADC Contract Manufacturers: Distribution by Scale of Operation
Table 35.10 ADC Contract Manufacturers: Distribution by Type of ADC Manufacturing Service Offered and Scale of Operation
Table 35.11 ADC Contract Manufacturers: Distribution by Location of Manufacturing Facilities and Type of ADC Manufacturing Service Offered
Table 35.12 Lonza: Annual Revenues, FY 2019-H1 FY 2023 (CHF Billion)
Table 35.13 WuXi Biologics: Annual Revenues, FY 2019-H1 FY 2023 (RMB Billion)
Table 35.14 Catalent Pharma Solutions: Annual Revenues, FY 2019 - FY 2023 (USD Billion)
Table 35.15 Recent Expansions: Cumulative Year-wise Trend, 2013-2023
Table 35.16 Recent Expansions: Distribution by Type of Expansion
Table 35.17 Recent Expansions: Distribution by Purpose of Expansion
Table 35.18 Recent Expansions: Distribution by Year of Expansion and Purpose of Expansion
Table 35.19 Recent Expansions: Distribution by Scale of Operation
Table 35.20 Recent Expansions: Distribution by Location of Expanded Facility
Table 35.21 Recent Expansions: Distribution by Location of Expanded Facility and Scale of Operation
Table 35.22 Most Active Players: Distribution by Number of Expansions
Table 35.23 Partnerships and Collaborations: Cumulative Year-wise Trend, 2012-2023
Table 35.24 Partnerships and Collaborations: Distribution by Type of Partnership
Table 35.25 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 35.26 Partnerships and Collaborations: Distribution by Purpose of Partnership
Table 35.27 Partnerships and Collaborations: Distribution by Scale of Operation
Table 35.28 Most Active Players: Distribution by Number of Partnership Instances
Table 35.29 Partnerships and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
Table 35.30 Partnerships and Collaborations: Distribution by Local and International Agreements
Table 35.31 Global Installed ADC Manufacturing Capacity: Distribution by Company Size
Table 35.32 Global Installed ADC Manufacturing Capacity: Distribution by Location of Headquarters
Table 35.33 Global Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (Region)
Table 35.34 Global Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (Country)
Table 35.35 Global Installed ADC Manufacturing Capacity: Distribution by Key Players
Table 35.36 Antibody Drug Conjugates: Distribution by Status of Development
Table 35.37 Antibody Drug Conjugates: Distribution by Target Disease Indication
Table 35.38 Antibody Drug Conjugates: Distribution by Therapeutic Area
Table 35.39 Antibody Drug Conjugates: Distribution by Line of Treatment
Table 35.40 Antibody Drug Conjugates: Distribution by Dosing Frequency
Table 35.41 Antibody Drug Conjugates: Distribution by Type of Therapy
Table 35.42 Antibody Drug Conjugates: Distribution by Target Antigen
Table 35.43 Antibody Drug Conjugates: Distribution by Antibody Isotype
Table 35.44 Antibody Drug Conjugates: Distribution by Payload / Cytotoxin / Warhead
Table 35.45 Antibody Drug Conjugates: Distribution by Type of Payload
Table 35.46 Antibody Drug Conjugates: Distribution by Linker
Table 35.47 Antibody Drug Conjugates: Distribution by Type of Linker
Table 35.48 Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2016-2023
Table 35.49 Clinical Trial Analysis: Distribution by Trial Status
Table 35.50 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status
Table 35.51 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2016-2023
Table 35.52 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, 2016-2023
Table 35.53 Clinical Trial Analysis: Distribution by Trial Phase
Table 35.54 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 35.55 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 35.56 Clinical Trial Analysis: Distribution by Target Population
Table 35.57 Clinical Trial Analysis: Distribution by Study Design
Table 35.58 Most Active Industry Players: Distribution by Number of Trials
Table 35.59 Most Active Non-Industry Players: Distribution by Number of Trials
Table 35.60 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Table 35.61 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Table 35.62 Global Demand for ADC Therapeutics, 2023-2035 (in kg)
Table 35.63 Global Demand for ADC Therapeutics: Distribution by Stage of Development, 2023-2035 (in kg)
Table 35.64 Global Commercial Demand for ADC Therapeutics, 2023-2035 (in kg)
Table 35.65 Global Commercial Demand for ADC Therapeutics: Distribution by Target Indication, 2023-2035 (in kg)
Table 35.66 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Origin, 2023-2035 (in kg)
Table 35.67 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2023-2035 (in kg)
Table 35.68 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Payload, 2023-2035 (in kg)
Table 35.69 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Linker, 2023-2035 (in kg)
Table 35.70 Global Commercial Demand for ADC Therapeutics: Distribution by Geography, 2023-2035 (in kg)
Table 35.71 Global Clinical Demand for ADC Therapeutics, 2023-2035 (in kg)
Table 35.72 Global Clinical Demand for ADC Therapeutics: Distribution by Phase of Development, 2023-2035 (in kg)
Table 35.73 Global Clinical Demand for ADC Therapeutics: Distribution by Target Indication, 2023-2035 (in kg)
Table 35.74 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Origin, 2022-2035 (in kg)
Table 35.75 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2023-2035 (in kg)
Table 35.76 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Payload, 2023-2035 (in kg)
Table 35.77 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Linker, 2023-2035 (in kg)
Table 35.78 Global Clinical Demand for ADC Therapeutics: Distribution by Geography, 2023-2035 (in kg)
Table 35.79 Global ADC Contract Manufacturing Market, Historical Trends and Forecasted Estimates, till 2035 (USD Billion)
Table 35.80 Global ADC Contract Manufacturing Market, Forecasted Estimates, till 2035, Conservative Scenario (USD Billion)
Table 35.81 Global ADC Contract Manufacturing Market, Forecasted Estimates, till 2035, Optimistic Scenario (USD Billion)
Table 35.82 Global ADC Contract Manufacturing Market: Distribution by Stage of Development, 2023, 2028 and 2035 (USD Billion)
Table 35.83 ADC Contract Manufacturing Market for Phase I ADCs, Forecasted Estimates, till 2035 (USD Billion)
Table 35.84 ADC Contract Manufacturing Market for Phase II ADCs, Forecasted Estimates, till 2035 (USD Billion)
Table 35.85 ADC Contract Manufacturing Market for Phase III ADCs, Forecasted Estimates, till 2035 (USD Billion)
Table 35.86 ADC Contract Manufacturing Market for Commercial ADCs, Forecasted Estimates, till 2035 (USD Billion)
Table 35.87 Global ADC Contract Manufacturing Market: Distribution by Process Component, 2023, 2028 and 2035 (USD Billion)
Table 35.88 ADC Contract Manufacturing Market for Antibody, Forecasted Estimates, till 2035 (USD Billion)
Table 35.89 ADC Contract Manufacturing Market for HPAPI / Cytotoxic Payload, Forecasted Estimates, till 2035 (USD Billion)
Table 35.90 ADC Contract Manufacturing Market for Conjugation / Linker, Forecasted Estimates, till 2035 (USD Billion)
Table 35.91 ADC Contract Manufacturing Market for Fill / Finish, Forecasted Estimates, till 2035 (USD Billion)
Table 35.92 Global ADC Contract Manufacturing Market: Distribution by Target Indication, 2023, 2028 and 2035 (USD Billion)
Table 35.93 ADC Contract Manufacturing Market for Solid Tumors, Forecasted Estimates, till 2035 (USD Billion)
Table 35.94 ADC Contract Manufacturing Market for Hematological Tumors, Forecasted Estimates, till 2035 (USD Billion)
Table 35.95 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Billion)
Table 35.96 Global ADC Contract Manufacturing Market: Distribution by Antibody Generation, 2023, 2028 and 2035 (USD Billion)
Table 35.97 ADC Contract Manufacturing Market for Second Generation, Forecasted Estimates, till 2035 (USD Billion)
Table 35.98 ADC Contract Manufacturing Market for Third Generation, Forecasted Estimates, till 2035 (USD Billion)
Table 35.99 ADC Contract Manufacturing Market for Fourth Generation, Forecasted Estimates, till 2035 (USD Billion)
Table 35.100 ADC Contract Manufacturing Market for Next Generation, Forecasted Estimates, till 2035 (USD Billion)
Table 35.101 Global ADC Contract Manufacturing Market: Distribution by Antibody Origin, 2023, 2028 and 2035 (USD Billion)
Table 35.102 ADC Contract Manufacturing Market for Human Origin, Forecasted Estimates, till 2035 (USD Billion)
Table 35.103 ADC Contract Manufacturing Market for Chimeric Origin, Forecasted Estimates, till 2035 (USD Billion)
Table 35.104 ADC Contract Manufacturing Market for Murine Origin, Forecasted Estimates, till 2035 (USD Billion)
Table 35.105 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Billion)
Table 35.106 Global ADC Contract Manufacturing Market: Distribution by Antibody Isotype, 2023, 2028 and 2035 (USD Billion)
Table 35.107 ADC Contract Manufacturing Market for IgG1, Forecasted Estimates, till 2035 (USD Billion)
Table 35.108 ADC Contract Manufacturing Market for IgG4, Forecasted Estimates, till 2035 (USD Billion)
Table 35.109 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Billion)
Table 35.110 Global ADC Contract Manufacturing Market: Distribution by Type of Payload, 2023, 2028 and 2035 (USD Billion)
Table 35.111 ADC Contract Manufacturing Market for Camptothecin, Forecasted Estimates, till 2035 (USD Billion)
Table 35.112 ADC Contract Manufacturing Market for Maytansinoid, Forecasted Estimates, till 2035 (USD Billion)
Table 35.113 ADC Contract Manufacturing Market for Auristatin, Forecasted Estimates, till 2035 (USD Billion)
Table 35.114 ADC Contract Manufacturing Market for DNA Topoisomerase I Inhibitor, Forecasted Estimates, till 2035 (USD Billion)
Table 35.115 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Billion)
Table 35.116 Global ADC Contract Manufacturing Market: Distribution by Type of Linker, 2023, 2028 and 2035 (USD Billion)
Table 35.117 ADC Contract Manufacturing Market for Maleimide, Forecasted Estimates, till 2035 (USD Billion)
Table 35.118 ADC Contract Manufacturing Market for SMCC, Forecasted Estimates, till 2035 (USD Billion)
Table 35.119 ADC Contract Manufacturing Market for Tetrapeptide-based linker, Forecasted Estimates, till 2035 (USD Billion)
Table 35.120 ADC Contract Manufacturing Market for Valine-citrulline, Forecasted Estimates, till 2035 (USD Billion)
Table 35.121 ADC Contract Manufacturing Market for Others, Forecasted Estimates, till 2035 (USD Billion)
Table 35.122 Global ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035 (USD Billion)
Table 35.123 ADC Contract Manufacturing Market in North America, Forecasted Estimates, till 2035 (USD Billion)
Table 35.124 ADC Contract Manufacturing Market in Europe, Forecasted Estimates, till 2035 (USD Billion)
Table 35.125 ADC Contract Manufacturing Market in Asia-Pacific and Rest of the World, Forecasted Estimates, till 2035 (USD Billion)
Table 35.126 Commercial ADC Contract Manufacturing Market, Forecasted Estimates, till 2035 (USD Billion)
Table 35.127 Commercial ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035 (USD Billion)
Table 35.128 Commercial ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035 (USD Billion)
Table 35.129 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Generation, Forecasted Estimates, till 2035 (USD Billion)
Table 35.130 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035 (USD Billion)
Table 35.131 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035 (USD Billion)
Table 35.132 Commercial ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035 (USD Billion)
Table 35.133 Commercial ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035 (USD Billion)
Table 35.134 Commercial ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035 (USD Billion)
Table 35.135 Clinical ADC Contract Manufacturing Market, Forecasted Estimates, till 2035 (USD Billion)
Table 35.136 Clinical ADC Contract Manufacturing Market: Distribution by Phase of Development, Forecasted Estimates, till 2035 (USD Billion)
Table 35.137 Clinical ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035 (USD Billion)
Table 35.138 Clinical ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035 (USD Billion)
Table 35.139 Clinical ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035 (USD Billion)
Table 35.140 Clinical ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035 (USD Billion)
Table 35.141 Clinical ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035 (USD Billion)
Table 35.142 Clinical ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035 (USD Billion)
Table 35.143 Clinical ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035 (USD Billion)

List of Companies and Organization

  1. AbbVie
  2. AbbVie Contract Manufacturing
  3. ABL Bio
  4. AbTis
  5. Abzena
  6. ACES Pharma
  7. ADC Biotechnology (Acquired by Sterling Pharma Solutions)
  8. ADC Therapeutics
  9. Adcentrx Therapeutics
  10. AIMEDBIO
  11. Ajinomoto
  12. Ajinomoto Bio-Pharma Services
  13. Almac
  14. Alphamab Oncology
  15. ALSA Ventures
  16. Alteogen
  17. Ambrx
  18. Amgen
  19. Angiex
  20. Araris Biotech
  21. Asana BioSciences
  22. Astellas Pharma
  23. AstraZeneca
  24. ATB Therapeutics
  25. Atreca
  26. Avipep Therapeutics
  27. Axplora
  28. Bayer
  29. BeiGene
  30. Bicycle Therapeutics
  31. BioAtla
  32. Biocytogen
  33. BioMed Valley Discoveries
  34. BiOneCure Therapeutics
  35. Bioqube Ventures
  36. Biosion
  37. Bio-Synthesis
  38. Bio-Thera Solutions
  39. BiVictriX Therapeutics
  40. BOC Sciences
  41. Bolt Biotherapeutics
  42. Boostimmune
  43. Bristol-Myers Squibb
  44. BSP Pharmaceuticals
  45. Byondis
  46. Cambrex
  47. CARBOGEN AMCIS
  48. Catalent Pharma Solutions
  49. Celltrion
  50. Centrose
  51. Cerbios-Pharma
  52. ChemPartner
  53. Corbus Pharmaceuticals
  54. Creative Biolabs
  55. Cristal Therapeutics
  56. CSPC Pharmaceutical
  57. CStone Pharmaceuticals
  58. CureMeta
  59. CytomX Therapeutics
  60. Daiichi Sankyo
  61. Dalton Pharma Services
  62. Dantari
  63. Debiopharm
  64. Diatheva
  65. Duality Biologics
  66. Eisai
  67. Elevation Oncology
  68. EMD Serono
  69. Emergence Therapeutics
  70. Exelixis
  71. Farmabios
  72. Formosa Laboratories
  73. Formosa Pharmaceuticals
  74. Fortis Therapeutics
  75. Fosun Pharma
  76. GBI
  77. Genentech
  78. GeneQuantum Healthcare
  79. Genmab
  80. Genor Biopharma
  81. Gilead Sciences
  82. Glycotope                                           
  83. GSK
  84. GTP Bioways
  85. Hangzhou Adcoris BioPharma
  86. Hangzhou DAC Biotech
  87. Harbour BioMed
  88. Heidelberg Pharma
  89. Hisun Pharmaceuticals
  90. Hummingbird Bioscience
  91. Iconic Therapeutics
  92. Iksuda Therapeutics
  93. ImmuneOncia Therapeutics
  94. ImmunoBiochem
  95. ImmunoGen
  96. Immunome 
  97. Innovent Biologics
  98. IntoCell
  99. iProgen Biotech
  100. KLUS Pharma (Subsidiary of Kelun-Biotech)
  101. Kodiak Sciences
  102. LaNova Medicines
  103. LegoChem Biosciences
  104. Lepu Biopharma
  105. Levena Biopharma
  106. Light Chain Bioscience
  107. Lonza
  108. Luzsana Biotechnology
  109. Mablink Bioscience
  110. MabPlex
  111. Mabwell (Shanghai) Bioscience
  112. Mabwell Therapeutics
  113. MacroGenics
  114. Magenta Therapeutics
  115. McSAF
  116. MediaPharma
  117. MediLink Therapeutics
  118. Megalith Pharmaceuticals
  119. Menarini
  120. Merck
  121. Mersana Therapeutics
  122. MilliporeSigma
  123. Mitsubishi Tanabe Pharma
  124. MuseChem
  125. Mythic Therapeutics
  126. NanoValent Pharmaceuticals
  127. Navrogen
  128. NBE-Therapeutics
  129. Nordic Nanovector
  130. NovaRock Biotherapeutics
  131. Novartis
  132. Novasep
  133. NovoCodex Biopharmaceuticals
  134. OBI Pharma
  135. OGD2 Pharma
  136. Oncolinx
  137. Oncomatryx Biopharma
  138. OnCusp Therapeutics
  139. Orano Med
  140. Oxford BioTherapeutics
  141. Paul Scherrer Institute
  142. Peak Bio
  143. Perseus Proteomics
  144. Pfizer
  145. Pheon Therapeutics
  146. Pierre Fabre
  147. PinotBio
  148. Piramal Pharma Solutions
  149. ProfoundBio
  150. Pyxis Oncology
  151. Rakuten Medical
  152. Recipharm
  153. Regeneron
  154. RemeGen
  155. Sanofi
  156. Sartorius
  157. Schengen Pharma
  158. Seagen
  159. Shanghai Fudan Zhangjiang Biopharmaceutical
  160. Shanghai Pharmaceuticals
  161. Shanghai Hansoh Biomedical
  162. Singzyme
  163. Sorrento Therapeutics
  164. SOTIO Biotech
  165. Sterling Pharma Solutions
  166. Sutro Biopharma
  167. Synaffix
  168. Syngene
  169. SystImmune
  170. Takeda
  171. Takeda Oncology
  172. Tanabe Research Laboratories
  173. Targinta (Subsidiary of Xintela)
  174. Toray Industries
  175. TOT BIOPHARM
  176. TRIO Pharmaceuticals
  177. Triphase Accelerator
  178. Tubulis
  179. UCB
  180. University Medical Center Groningen
  181. Vincerx Pharma
  182. WuXi Biologics
  183. WuXi STA (A subsidiary of WuXi AppTec)
  184. Y-Biologics
  185. Zhejiang Teruisi Pharmaceutical
  186. Zydus Lifesciences
  187. Zymework

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com